Published 6/25/2021

Course description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Hematologic Malignancies, provides an overview of the various treatment approaches to hematologic malignancies. This module will provide an overview of the major immunotherapies in development, FDA-approved treatments as well as the side effects associated with those treatments, and current clinical trials.  Learners will have an opportunity to apply what they've learned through two case studies.  By the end of the course, participants will be better able to implement immunotherapy for the treatment of hematologic malignancies.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

Credit Available:  June 25, 2021 - June 25, 2022

Estimated time to complete activity: 45 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Discuss the purpose of immune checkpoint inihibitors, as well as identify which have been approved by the FDA.
• Recognize antibody-drug conjugates (ADCs), which have been FDA-approved, and appropriate malignancies for which ADCs would be effective.
• Identify bispecific antigens' role in immunotherapy.
• Describe cellular therapies, including CAR T cell therapies and the side effects, current FDA approvals, and clinical trials in development.

Faculty
Hongtao Liu, MD, PhD

Associate Professor of Medicine

Co-Director, Combined Apheresis Unit

Medical Director, Clinical Cellular Labratory Section of Hematology/Oncology

Department of Medicine, University of Chicago

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

Hongtao Liu, MD, PhD - Consulting Fees: Agios Pharmaceuticals; BeiGene, NGM Biopharmarmaceuticals. Contracted Research: BMS; Karyopharm, Miltenyi.

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1.  After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for "Immunotherapy for the Treatment of Hematologic Malignancies."
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete the post-test with a passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: You must provide your NABP ePID and date of birth in MM/DD format.  Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-21-2839-H01-P)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

Published July 28, 2021

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, What's Next in Cancer Immunotherapy, provides an overview of several publications researching the conditions and stresses of the tumor microenvironment, as well as discussing some of the major factors impacting those providing and receiving immunotherapy treatments.  At the end of this course, participants have a better understanding not only of stress sensor impacting tumor cell growth, but also some of the major hurdles affecting immunotherapy's progression. 

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

Credit Available:  July 28, 2021 - July 28, 2022

Estimated time to complete activity: 45 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify three stress sensors impacting the endoplasmic reticulum.
• Explain why targeting the cell's response to these stress sensors may be the key to immunotherapy treatments.
• Identify several of the major hurdles impacting current and future cancer immunotherapy.

Faculty
Jessica Thaxton, PhD, MsCR

Assistant Professor

Hollings Cancer Center, Medical University of South Carolina

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

Jessica Thaxton, PhD, MsCR: Research grants TEVA Pharmaceuticals

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1.  After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for "What's Next in Cancer Immunotherapy?"
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete the post-test with a passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: You must provide your NABP ePID and date of birth in MM/DD format.  Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-21-2862-H01-P)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

Published May 21, 2021

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Lung Cancer, provides an overview of immunotherapy treatment for lung cancer. Multiple clinical trials dealing with both non-small cell lung cancer and small cell lung cancer are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through two in-depth case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for lung cancers.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

Credit Available:  May 21, 2021 - May 21, 2022

Estimated time to complete activity: 45 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Implement cancer immunotherapy treatment for lung cancer.
• Identify immune-related toxicities related to lung cancer immunotherapy agents.
• Describe the rationale for common approaches to cancer immunotherapy.

Faculty
Jennifer Carlisle, MD

Assistant Professor

Emory University

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships with ineligible entities related to the education content of this CE activity: 

Jennifer Carlisle, MD: Nothing to disclose.

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1.  After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for "Immunotherapy for the Treatment of Lung Cancer."
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete the post-test with a passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: You must provide your NABP ePID and date of birth in MM/DD format.  Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour. Designated for 0.4 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-21-2718-H01)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

Published May 13, 2021

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer's (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at https://www.sitcancer.org/education/aci/online.

This course, Immunotherapy for the Treatment of Breast and Gynecologic Cancers, provides an overview of the currently-approved treatments used to treat both breast and gynecologic cancers, as well as a synopsis of future potential applications of immunotherapy for these cancers.  Several clinical trials and two case studies are discussed, allowing the learner to better understand the current use of immunotherapy as well as how clinical trials are leading the way to additional use of immunotherapy for both types of cancer.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

Credit Available: May 13, 2021 - May 13, 2022

Estimated time to complete activity: 30 minutes

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the early stage application of breast and gynecologic cancer immunotherapy treatment in relation to standard-of-care therapies
• Select cancer immunotherapy treatment for breast and gynecologic cancer and better manage common side effects
• Describe the rationale for common approaches to cancer immunotherapy

Faculty
Megan Kruse, MD

Associate Staff Physician

Hematology and Medical Oncology

Cleveland Clinic

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Megan Kruse, MD: Consulting Fees: Puma biotechnology, Immunomedics, Eisai, Seattle Genetics, Lilly Oncology, Novartis Oncology.   Contracted Research: Tempus.

The PIM planners and others have nothing to disclose. The Society for Immunotherapy of Cancer planners and others have nothing to disclose. 
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period of accreditation, participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for "Immunotherapy for Treatment of Breast and Gynecologic Cancers" 
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete the post-test with a passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: You must provide your NABP ePID and date of birth in MM/DD format. Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
 

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advance Practice Registered Nurses.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-21-2714-H01-P)

Type of Activity: Knowledge

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 

Published February 23, 2021

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Practical Barriers in Cancer Immunotherapy Treatment, provides a detailed overview of how to overcome barriers to obtaining reimbursement from both Medicare and commercial payers for the use of immunotherapy in cancer treatment.
 

At the end of this course, participants will be able to identify solutions to overcome both operational and financial barriers to integrating immunotherapy into their practice setting.

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Sigrun Hallmeyer, MD

Medical Director, Cancer Service Line

Medical Director, Cancer Survivorship Center

Advocate Lutheran General Hospital

Chair, Executive Committee

Association of Community Cancer Centers, Immuno-Oncology Institute

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify and implement solutions to overcome operational barriers to implementing cancer immunotherapy in the clinical setting. 
• Identify and implement solutions to overcome financial barriers to implementing cancer immunotherapy in the clinical setting.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Credit Available: February 23, 2021 - February 23, 2022

Estimated time to complete activity: 1.25 hours

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-21-2606-H01-P)

Type of Activity: Application

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Sigrun Hallmeyer, MD: Consulting Fees: Bristol Myers Squibb; Cardinal Health; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents: Bristol Myers Squibb

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period February 23, 2021 through February 23, 2022 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for "Practical Barriers in Cancer Immunotherapy Treatment." 
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete the post-test with a passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Published December 24, 2020

Course Description

This interactive course provides an overview of the mechanisms by which cancer immunotherapy may activate immune-related adverse events (irAEs). The foundational knowledge presented in this course is critical to understanding how and why immune-related adverse events occur and how they can be treated.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Pradnya Patil, MD, FACP

Hematology/Oncology Fellow

Taussig Cancer Institute, Cleveland Clinic

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Discuss the mechanisms of peripheral and central immune tolerance.
• Describe the biological pathways involved in mediating autoimmune reactions.
• Explain the differences between PD-1 and CTLA-4 pathway-mediated autoimmunity.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Credit Available: December 24, 2020 - December 24, 2021

Estimated time to complete activity: 0.5 hour

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2020-2021 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Exelixis, Inc., and Merck & Co., Inc. 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2520-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.  Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Pradnya Patil, MD, FACP: Nothing to disclose

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period December 24, 2020 through December 24, 2021 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for "Mechanisms of Immune-Related Adverse Events." 
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete the post-test with a passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

This version of the course is no longer available for credit. To access the accredited version go here to find the Immunotherapy for the Treatment of Breast and Gynecologic Cancers that is a CME-, CPE-, CNE- and MOC-certified activity.

Published August 11, 2020

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Breast and Gynecologic Cancers, provides an overview of the still emerging applications of Breast and Gynecologic Cancer Immunotherapy. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for Breast and Gynecologic Cancer.
 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

Evanthia Roussos Torres, MD, PhD
Assistant Professor of Medicine, Oncology
University of Southern California
Norris Comprehensive Cancer Center
 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the early stage application of breast and gynecologic cancer immunotherapy treatment in relation to standard-of-care therapies
• Implement cancer immunotherapy treatment for breast and gynecologic cancer and better manage common side effects
• Describe the rationale for common approaches to cancer immunotherapy
   

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: 8/11/20 - 8/11/21

Approximate Time to Complete:  45 minutes
 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2249-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

Evanthia Roussos Torres, MD, PhD: Nothing to disclose

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 8/11/20 through 8/11/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Breast & Gynecologic Cancers.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

Please note, this course is no longer eligible to receive CE credits.

Published July 29,2020

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Microsatellite Instability (MSI) – High Cancers, provides background on MSI and an overview of immunotherapy treatment for MSI-high populations. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for MSI-high cancers.
 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

John C. Leighton, Jr., MD
Division Chair, Hematology and Medical Oncology
Einstein Healthcare Network

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe microsatellite instability and the implications for immunotherapy treatment
• Provide cancer immunotherapy treatment for microsatellite instability – high cancers
• Describe the rationale for common approaches to cancer immunotherapy
   

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: 7/29/20 - 7/29/21

Approximate Time to Complete:  45 minutes
 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2214-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.2 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

John C. Leighton, Jr., MD: Nothing to disclose

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 7/29/20 through 7/29/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Microsatellite Instability (MSI) – High Cancers.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

This version of the course is no longer available for credit.  To access the accredited version, go here to find the Immunotherapy for the Treatment of Lung Cancer that is a CME-, CPE-, CNE-, and MOC-certified activity. 

Published July 15, 2020

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Lung Cancer, provides an overview of immunotherapy treatment for lung cancer. Multiple clinical trials dealing with both non-small cell lung cancer and small cell lung cancer are discussed, as are key findings that have resulted in recent FDA approvals.  Learners will have an opportunity to interactively apply what they've learned through an in-depth case study. At the end of this course, participants will be better able to implement immunotherapy treatment for lung cancers.
 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

Deepa Rangachari, M.D.
Assistant Professor of Medicine, Harvard Medical School
Thoracic Oncology Program, Beth Israel Deaconess Medical Center
 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Implement cancer immunotherapy treatment for lung cancer.
• Identify the appropriate clinical management of common side effects of immunotherapy agents.
• Describe the rationale for common approaches to cancer immunotherapy.
   

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available:  July 15, 2020 - July 15, 2021

Approximate Time to Complete: 60 minutes

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2190-H01)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

Deepa Rangachari, MD: Contracted research support from Bristol Myers Squibb, Novocure, and Abbvie/Stemcentrx; consulting fees from Astra Zeneca, DynaMed, and Advance Medical/Teladoc Health

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 7/15/20 through 7/15/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Lung Cancer.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

This course is no longer available for credit.

Originally published May 26, 2020 (Updated June 9. 2020)

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Hepatocellular Carcinoma (HCC), provides an overview of liver immunobiology and immunotherapeutic strategies in HCC, including checkpoint inhibition, blocking inhibitory cytokines, vaccine therapies, oncolytic viruses, and adoptive cell therapy. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for HCC.
 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

Anuradha Krishnamurthy, MD
Assistant Professor of Medicine
University of Pittsburgh School of Medicine
 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the characteristics of liver immunobiology
• Implement cancer immunotherapy treatment for HCC and better manage common side effects
• Describe the rationale for common approaches to cancer immunotherapy
   

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: 5/26/20 - 5/26/21

Approximate Time to Complete:  45 minutes
 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2142-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

Anuradha Krishnamurthy, MD: Nothing to disclose

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 5/26/20 through 5/26/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Hepatocellular Carcinoma.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

This course is no longer available for credit. 

Published May 26, 2020

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Skin Cancers, provides the latest in immunotherapy treatment for skin cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for skin cancers.
 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

Ryan J. Sullivan, MD
Assistant Professor of Medicine
Harvard Medical School, Boston, MA
Division of Hematology/Oncology, Department of Medicine
Massachusetts General Hospital, Boston MA

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the rationale for common approaches to cancer immunotherapy.
• Implement cancer immunotherapy treatment for skin cancers. 
• Identify common side effects of immunotherapy agents.
   

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: 5/26/20 - 5/26/21

Approximate Time to Complete:  75 minutes
 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (.125 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2143-H01-P)

Type of Activity: Application

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.3 contact hours. Designated for 1.0 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

Ryan J. Sullivan, MD: Consulting Fees (Merck, Novartis, Replimune, Bristol Myers Squibb, Asana Biosciences); Contracted Research (Merck, Amgen)

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 5/26/20 through 5/26/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Skin Cancers.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

Originally published April 30, 2020 (updated May 7, 2020)

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Head and Neck Cancer, provides an overview of immunotherapy treatment for head and neck cancer. Multiple clinical trials are discussed, including both mono- and combination therapies.  Learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for head and neck cancer.
 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

Michael Gibson, MD, PhD FACP
Associate Professor of Medicine
Director of Translational Research for Head and Neck Oncology
Director of Translational Therapeutics for Esophago-Gastric Oncology
Vanderbilt-Ingram Cancer Center
Vanderbilt University Medical Center
 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe rationale for common approaches to cancer immunotherapy.
• Implement cancer immunotherapy treatments for head and neck cancers. 
• Identify appropriate clinical management of common side effects of immunotherapy agents. 
   

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: 4/30/20 - 4/30/21

Approximate Time to Complete:  45 minutes
 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2066-H01-P)

Type of Activity: Application

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

Michael Gibson, MD, PhD: Consulting fees to Merck, Bristol-Myers Squibb; Fees for Non-CME/CE services received directly from a commercial interest or their agents to Bristol-Myers Squibb (non-branded)

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 4/30/20 through 4/30/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Head and Neck Cancer.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Firefox, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

Originally published March 31, 2020 (updated May 7, 2020)

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Genitourinary Malignancies, provides an overview of immunotherapy treatment for the genitourinary malignancies renal cell carcinoma, urothelial carcinoma, and prostate cancer. Multiple clinical trials are discussed, including both mono- and combination therapies.  Learners will have an opportunity to interactively apply what they've learned through three case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for genitourinary malignancies.
 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

Pedro Barata, MD, MSc
Assistant Professor of Medicine
Deming Department of Medicine
Section of Hematology/Oncology
Tulane University School of Medicine
 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe rationale for common approaches to cancer immunotherapy.
• Implement cancer immunotherapy treatments for genitourinary malignancies. 
• Identify appropriate clinical management of common side effects of immunotherapy agents. 
   

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: 3/31/20 - 3/31/21

Approximate Time to Complete:  1 hour
 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2051-H01-P)

Type of Activity: Application

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.8 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

Pedro Barata, MD, MSc: Consulting Fees (Exelixis, Caris, Bayer, Janssen, EMD-Serono, Pfizer, Astellas, Dendreon, Clovis, Eisai, Sanofi); Contracted Research (BlueEarth Diagnostics, Nektar, AstraZeneca and Seattle Genetics)

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 3/31/20 through 3/31/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Genitourinary Malignancies.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Firefox, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

This version of the course is no longer available for credit.  To access the accredited version, go here to find the What's Next in Cancer Immunotherapy that is a CME-, CPE-, CNE-, and MOC-certified activity.

Published February 11, 2020

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, What's Next for Cancer Immunotherapy?, covers the future of cancer immunotherapy such as understanding important trends, new developments, potential approvals and disease states with promising data.
 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

Evan J. Lipson, MD
Associate Professor, Department of Oncology
Johns Hopkins University School of Medicine

Parul Agarwal, MD
Medical Oncology Fellow
Johns Hopkins University School of Medicine
 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the rationale behind expanding the settings in which cancer immunotherapy is administered, including patients with a larger variety of tumor types and patient populations previously excluded from clinical trial participation.
• Describe the basis for novel immunotherapy drug combinations.
   

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: 2/11/20 - 2/11/21

Approximate Time to Complete:  45 minutes
 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-1083-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.4 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

Evan J. Lipson, MD: Consultant (Bristol-Myers Squibb, Novartis, EMD Serono, Array BioPharma, Macrogenics, Merck); Contracted Research (Bristol-Myers Squibb, Merck)
 

Parul Agarwal, MD: Nothing to Disclose

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 2/11/20 through 2/11/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for What's Next for Cancer Immunotherapy?
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

Please note this course is no longer available for credit.   Click here to access the current version of Immunotherapy for the Treatment of Hematologic Malignancies which is a CME-, CPE-, CNE-, and MOC-certified activity.

Originally published January 23, 2020 (Updated May 7, 2020)

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Immunotherapy for the Treatment of Hematologic Malignancies, provides the latest in immunotherapy treatment for hematological cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. Several clinical trials are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to implement immunotherapy treatment for hematologic cancers.
 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

Bhagirathbhai R. Dholaria, MBBS
Assistant Professor
Department of Hematology - Oncology
Vanderbilt University School of Medicine, Nashville, TN
 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the rationale for common approaches to cancer immunotherapy.
• Implement cancer immunotherapy treatment for hematologic cancers. 
• Identify common side effects of immunotherapy agents.
   

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: 1/23/20 - 1/23/21

Approximate Time to Complete:  45 minutes
 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-1072-H01-P)

Type of Activity: Application

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hours. Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

Bhagirathbhai R. Dholaria, MBBS: Celgene (consulting)

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 1/23/20 through 1/23/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for Immunotherapy for the Treatment of Hematologic Malignancies.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

Published January 16, 2020

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Toxicity Management, provides an overview of clinical toxicity management for cancer immunotherapy. Both common and uncommon immune-related adverse events (irAEs) are discussed and learners will have an opportunity to interactively apply what they've learned through two case studies. At the end of this course, participants will be better able to manage immune-related adverse events for patients receiving cancer immunotherapy.
 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

Morgan Gwynn, PharmD, BCOP, CPP
Melanoma and Head & Neck Oncology Clinical Pharmacist Practitioner
University of North Carolina Medical Center
 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify common and uncommon immune-related adverse events associated with cancer immunotherapy
• Describe best practices for managing common side effects seen in cancer immunotherapy treatment

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: 1/16/20-1/16/21

Approximate Time to Complete:  45 minutes
 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-1068-H01-P)

Type of Activity: Application

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hour.  Designated for 0.7 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

Morgan Gwynn, PharmD, BCOP, CPP: Nothing to disclose

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 1/16/20 through 1/16/21 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for Toxicity Management.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

This version of the course is no longer available for credit. To access the accredited version go here to find the Mechanisms of Immune-Related Adverse Events that is a CME-, CPE-, CNE- and MOC-certified activity.

Published December 23, 2019

Course Description

This interactive course provides an overview of the mechanisms by which cancer immunotherapy may activate immune-related adverse events (irAEs). The foundational knowledge presented in this course is critical to understanding how and why immune-related adverse events occur and how they can be treated.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Pradnya Patil, MD, FACP

Hematology/Oncology Fellow

Taussig Cancer Institute, Cleveland Clinic

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Discuss the mechanisms of peripheral and central immune tolerance.
• Describe the biological pathways involved in mediating autoimmune reactions.
• Explain the differences between PD-1 and CTLA-4 pathway-mediated autoimmunity.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Credit Available: December 23, 2019 - December 23, 2020

Estimated time to complete activity: 0.5 hour

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-887-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.  Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Pradnya Patil, MD, FACP: Nothing to disclose

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period December 23, 2019 through December 23, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for "Mechanisms of Immune-Related Adverse Events." 
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete the post-test with a passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Published December 17, 2019

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.
 

This Basic Principles of Cancer Immunotherapy course covers the basic principles and mechanisms behind cancer immunotherapy.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, advanced practice registered nurses, and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

Stefani Spranger, PhD
Assistant Professor of Biology
Koch Institute for Integrative Cancer Research at MIT
 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the rationale for common approaches to cancer immunotherapy

• Recognize various approaches to cancer immunotherapy including therapeutic vaccine, adoptive cell transfer, cytokines, checkpoint inhibitor modulation, effector antibodies and antibody-drug conjugates

• Explain the mechanism by which tumors evade the immune system and mechanisms to overcome this immunosuppression

• List important biomarkers for measuring the immune response

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: 12/17/19-12/17/20

Approximate Time to Complete:  45 minutes
 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-991-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. Designated for 0.3 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

Stefani Spranger, PhD: Consulting fees to Venn Therapeutic, Tango, Takeda, Replimune, Ribon, Dragonfly, Merck, Torque; Contracted Research to Takeda, Exelixis

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 12/17/19 through 12/17/20 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for Basic Principles of Cancer Immunotherapy.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Google Chrome, Firefox, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

This course is no longer available for credit. Please access the updated course, Practical Barriers in Cancer Immunotherapy Treatment, which is a CME-, CPE-, CNE- and MOC-certified activity.

Published December 10, 2019

Course Description

This interactive online course is part of the Society for Immunotherapy of Cancer’s (SITC) Advances in Cancer Immunotherapy™ (ACI) program. Designed for oncologists, nurses, pharmacists, emergency physicians and all members of the cancer team, the ACI program focuses on recent clinical advancements, management of immune-related adverse events, underlying mechanisms of different immunotherapy options, clinical application for various disease states, and what to look for in the future. View all available ACI online offerings at www.sitcancer.org/acionline.

This course, Practical Barriers in Cancer Immunotherapy Treatment, provides a detailed overview of how to overcome barriers to obtaining reimbursement from both Medicare and commercial payers for the use of immunotherapy in cancer treatment.
 

At the end of this course, participants will be able to identify solutions to overcome both operational and financial barriers to integrating immunotherapy into their practice setting.
 

Target Audience

This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

Amy Schippers, PA-C
Physician Assistant
St. Luke's University & Health Network
 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify and implement solutions to overcome operational barriers to implementing cancer immunotherapy in the clinical setting. 
• Identify and implement solutions to overcome financial barriers to implementing cancer immunotherapy in the clinical setting.
   

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: 12/10/19-12/10/20

Approximate Time to Complete:  45 minutes
 

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy^TM educational series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc.
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour (.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-983-H04-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hour.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.
 

Faculty

Amy Schippers, PA-C: Nothing to Disclose

Planners and Managers

The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period 12/10/19 through 12/10/20 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for Practical Barriers in Cancer Immunotherapy Treatment.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Edge, Apple Safari, Firefox, Google Chrome, Internet Explorer 7+) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com

This course is no longer available for continuing education credits. Further, this course has been replaced by Module 1 of the SITC Certificate in Cancer Immunotherapy program, Basic Immunology Concepts, as serving as one of the pre-program courses for the ACI Live Virtual events. If you've registered for an ACI Live Virtual event you should have received a coupon code to take Basic Immunology Concepts for free.
 

Course Description

This interactive course provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy. 

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Christian M. Capitini, MD
Assistant Professor
University of Wisconsin Carbone Cancer Center

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the function of the components of the immune system, including relevant cells, molecules and organs of the immune system.
• Differentiate between the adaptive immune system and the innate immune system.
• Recognize the barriers to effective immunotherapy, including mechanisms by which tumors locally disable and/or evade the immune system. 

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

Continuing Education Information

Credit Available: October 9, 2019 - October 9, 2020

Estimated time to complete activity: 1 hour

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

The 2019-2020 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc. 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-884-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.  Designated for 0.5 pharmacotherapy contact hour for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Christian Capitini, MD: Nothing to disclose

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period October 9, 2019 through October 9, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please follow the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for "Introduction to Immunology – Third Edition."
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Access the updated course, Immunotherapy for the Treatment of Hematologic Malignancies.

Immunotherapy for the Treatment of Hematologic Malignancies, is a CME-, CPE-, CNE- and MOC-certified activity.

Please note that continuing education credit for 2019 Interactive Course: Hematologic Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™) is only available through May 3, 2019.
 

Course Description

This interactive course provides an overview of the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The course also provides the latest in immunotherapy treatment for hematological cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. After completing this course, learners will gain an understanding of common approaches to cancer immunotherapy; how to implement cancer immunotherapy treatment for hematologic cancers and how to identify and manage common side effects of immunotherapy agents.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Naval Daver, MD

Associate Professor

University of Texasw MD Anderson Cancer Center

and

Christian Capitini, MD

Assistant Professor

University of Wisconsin - Madison Carbone Cancer Center

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the rationale for common approaches to cancer immunotherapy.
• Implement cancer immunotherapy treatment for hematologic cancers. 
• Identify the appropriate clinical management of common side effects of immunotherapy agents.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: May 3, 2019 - May 3, 2020

Approximate Time to Complete:  30 minutes

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-607-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours. Designated for 0.2 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.

Faculty
Naval Daver, MD - Consulting Fees - Pfizer, Otsaka, BMS, Daiichi-SanKyo, Jazz, Abbvie, Novartis and  Contracted Research - Pfizer, BMS, Incyte,Sunesis, Karyopharm, Daiichi-SanKyo, Servier, Genentech, Abbvie, Glycomimetics

Christian Capitini, MD - Consulting Fee - Nektar Therapeutics

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Tara Withington, CAE, Executive Director of SITC, has an ownership interest as a partner at Executive Director, Inc.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 30, 2019 through April 30, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please following the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for 2019 Interactive Course: Hematological Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Complete the post-test and survey.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Access the updated course, Immunotherapy for the Treatment of Skin Cancers.

Immunotherapy for the Treatment of Skin Cancers, is a CME-, CPE-, CNE- and MOC-certified activity.

Course Description

This interactive course provides an overview of the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The course also provides the latest in immunotherapy treatment for melanoma and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. After completing this course, learners will gain an understanding of common approaches to cancer immunotherapy; how to implement cancer immunotherapy treatment for melanoma and how to identify and manage common side effects of immunotherapy agents.

Target Audience
This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Isabella Glitza, MD, PhD

Oncologist 

University of Texas MD Anderson Cancer Center

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the rationale for common approaches to cancer immunotherapy.
• Implement cancer immunotherapy treatment for melanoma.
• Identify the appropriate clinical management of common side effects of immunotherapy agents.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed.  Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: May 1, 2019 - May 1, 2020

Approximate Time to Complete:  45 minutes

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-606-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.5 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Isabella Glitza, MD, PhD - Research - Bristol Myers Squib

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. Tara Withington, CAE, Executive Director of SITC, has an ownership interest as a partner at Executive Director, Inc.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 24, 2019 through April 24, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please following the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for 2019 Interactive Course: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™)
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Complete the post-test and survey.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Course Description

Exemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

The Immunotherapy for the Treatment of Head and Neck Cancer module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of head and neck cancers. The module also includes case studies on immunotherapy for the treatment of head and neck cancers.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty
Glenn J. Hanna, MD

Medical Oncologist, Dana-Farber Cancer Institute

Dana-Farber Cancer Institute 

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the rationale for common approaches to cancer immunotherapy in treatment of head and neck cancer patients
• Identify the appropriate clinical management of common side effects of immunotherapy agents
• Implement cancer immunotherapy treatments for Head and Neck cancers

Continuing Education Information

Approximate Time to Complete: One hour and 45 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (0.175 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-730-H04-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.7 contact hours.  Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Glenn J. Hanna, MD: Institutional support from BMS and EMD Serono

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please following the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for the appropriate course title.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Complete the post-test and survey.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Access the updated course, Immunotherapy for the Treatment of Genitourinary Malignancies

Immunotherapy for the Treatment of Genitourinary Malignancies, is a CME-, CPE-, CNE- and MOC-certified activity.
 

Course Description

This interactive course provides an overview of the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The course also provides the latest in immunotherapy treatment for genitourinary cancer, including kidney, bladder and prostate cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. After completing this course, learners will gain an understanding of common approaches to cancer immunotherapy; how to implement cancer immunotherapy treatment for genitourinary cancer (kidney, bladder and prostate cancers), and how to identify and manage common side effects of immunotherapy agents.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

Faculty
Lauren Harshman, MD

Assistant Professor and Co-director, Kidney Cancer Program

Dana-Farber Cancer Institute

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the rationale for common approaches to cancer immunotherapy.
• Implement cancer immunotherapy treatment for genitourinary cancers. 
• Identify the appropriate clinical management of common side effects of immunotherapy agents.

SITC Online Education Disclaimer

A qualified healthcare professional should be consulted before using any therapeutic product discussed.  Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Continuing Education Information

Credit Available: March 28, 2019 - March 28, 2020

Approximate Time to Complete:  45 minutes

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-608-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.4 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.

Faculty
Lauren Harshman, MD - Advisory/Research to Bayer, Exelixis, Genentech, Dendreon/Valient, Pfizer, Medivation/Astellas, Kew Group, Theragene, Corvus, Merck, Bristol-Meyers Squib, Jannsen, Sotio, Takeda, Sanofi, Novartis, Applied Clinical Education, PER

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Tara Withington, CAE, Executive Director of SITC, has an ownership interest as a partner at Executive Director, Inc.

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period March 28, 2019 through March 28, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please following the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for 2019 Interactive Course: Genitourinary Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Complete the post-test and survey.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Course Description

Exemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

The Basic Prinicples of Cancer Immunotherapy module covers the basic principles and mechanisms behind cancer immunotherapy.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty
Theodore F. Logan, MD

Associate Professor, Medicine

Indiana University Simon Cancer Center

Learning Objectives 

At the conclusion of this activy, the participants should be able to:

• Describe the rationale for common approaches to cancer immunotherapy

• Recognize various approaches to cancer immunotherapy including therapeutic vaccine, adoptive cell transfer, cytokines, checkpoint inhibitor modulation, effector antibodies and antibody-drug conjugates

• Explain the mechanism by which tumors evade the immune system and mechanisms to overcome this immunosuppression

• List important biomarkers for measuring the immune response

Continuing Education Information

Approximate Time to Complete: 45 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 

 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-727-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.1 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Theodore F. Logan, MD: Consulting - Prometheus Laboratories; Contracted Research - Abbott Laboratories, Abraxix BioSciences, Acceleron Pharma, Amgen, Argos Therapeutics, AstraZeneca, AVEO, BioVex, Breistol-Myers Squibb, Eisai, Lilly, GlaxoSmithKline, Roche, Immatics, Merck, Novartis, Pfizer, Synta, Threshold Pharmaceuticals, Mellennium, TRACON Pharma, Cerulean Pharma, EMD Serono, Prometheus Laboratories, Macrogenics, Peloton Therapeutics, Iovance Biotherapeutics, MedImmune, Dynavax

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please following the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for the appropriate course title.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Complete the post-test and survey.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Course Description

Exemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

The What's Next for Cancer Immunotherapy module covers the future of cancer immunotherapy such as understanding important trends, new developments, potential approvals and disease states with promising data.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty
Christian Capitini, MD

Assistant Professor, Medicine

University of Wisconsin Carbone Cancer Center

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the rationale for common approaches to cancer immunotherapy.
• Become familiar with clinical data on the efficacy and mechanism of action of approved therapies.

Continuing Education Information

Approximate Time to Complete: 30 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-734-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.  Designated for 0.2 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Christian Capitini, MD: Consulting Fees - Nektar Therapeutics 

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please following the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for the appropriate course title.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Complete the post-test and survey.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Course Description

Exemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

The Immunotherapy for the Treatment of Melanoma module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of melanoma. The module also includes case studies on immunotherapy for the treatment of melanoma.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty
Elizabeth Buchbinder, MD

Instructor, Medicine, Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the rationale for common approaches to cancer immunotherapy in treatment of melanoma patients
• Identify the appropriate clinical management of common side effects of immunotherapy agents
• Implement cancer immunotherapy treatments for melanoma
• Describe clinical efficacy of approved immunotherapies
• Recognize patient selection criteria for different immunotherapies
• Identify factors influencing dosing and choice of immunotherapy relative to other therapies for melanoma

Continuing Education Information

Approximate Time to Complete: 45 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-729-H01-P) 

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.6 contact hours. Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Elizabeth Buchbinder, MD: Consulting Fees - Array Pharmaceuticals; Salary - Sanofi

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please following the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for the appropriate course title.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Complete the post-test and survey.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Course Description

Exemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

The Immunotherapy for the Treatment of Lung Cancer module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of lung cancer. The module also includes case studies on immunotherapy for the treatment of lung cancer.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty
Deepa Rangachari, MD

Instructor, Medicine, Harvard Medical School

Beth Israel Deaconess Medical Center

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Discuss the clinical data on the efficacy and mechanism of action of approved therapies

• Recognize patient selection criteria for approved therapies

• Describe appropriate dosing and sequencing therapies

• Identify the appropriate clinical management of common side effects of immunotherapy agents

•  Implement cancer immunotherapy for the treatment of lung cancers

• Describe the rationale for common approaches to cancer immunotherapy in treatment of naive NSCLC patients

• Explain the role of biomarkers associated with response or lack of response to immunotherapy including PD-L1, tumor mutational burden (TMB), and epidermal growth factor receptor (EGFR)

Continuing Education Information

Approximate Time to Complete: 45 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc.

 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-728-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.4 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Deepa Rangachari, MD: No conflict of interest to report.

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please following the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for the appropriate course title.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Complete the post-test and survey.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Course Description

Exemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

The Immunotherapy for the Treatment of Hematologic Malignancies module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of hematologic malignancies. The module also includes case studies on immunotherapy for the treatment of hematologic malignancies.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty
Nirav Shah, MD

Assistant Instructor, Medicine

Medical College of Wisconsin

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Describe the rationale for common approaches to cancer immunotherapy for hematologic malignancies
• Identify the appropriate clinical management of common side effects of immunotherapy agents
• Implement cancer immunotherapy for Hematologic Malignancies
• Become familiar with clinical data on the efficacy and mechanism of action of approved therapies
• Recognize patient selection criteria for approved therapies
• Select appropriate dosing and sequencing of approved therapies

Continuing Education Information

Approximate Time to Complete: One hour and 45 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 

 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (0.175 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-731-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.7 contact hours.  Designated for 0.5 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Nirav Shah, MD: Consulting fees - Juno Therapeutics, Contracted Research - Lentigen Technology, Ownership Interest - Exelexis, Geron, Oncosec

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please following the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for the appropriate course title.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Complete the post-test and survey.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Access the updated course, Practical Barriers in Cancer Immunotherapy Treatment.

Practical Barriers in Cancer Immunotherapy Treatment, is a CME-, CPE-, CNE- and MOC-certified activity.

Please note that continuing education credit for 2019 Video Series: Practical Barriers in Cancer Immunotherapy (Advances in Cancer Immunotherapy^TM) is only available through April 25, 2020.

Course Description

Exemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

The Practical Barriers in Cancer Immunotherapy module covers practical barriers to implementing immunotherapy in a community setting (operations and reimbursement).. The module also includes a panel discussion in which experts in the field discuss common challenges they have faced including coverage and reimbursement challenges and adverse event managment.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty
Ryan Weight, DO, MD

Assistant Professor

University of Colorado

Monique Giordana, PharmD, BCOP

Hematology/Oncology Clinical Pharmacy Specialist 

Regions Hospital 

Lisa A. Kottschade, APRN, MSN, CNP

Associate Professor of Oncology/Nurse Practitioner

Mayo Clinic

Jodi Nordberg

Billing Operations Manager

UM Physicians

Sara Smith, PharmD, BCOP

Oncology Clinical Pharmacist

University of Minnesota Heath Maple Grove

Learning Objectives

At the conclusion of this activity, the participant should be able to:

• Identify solutions to overcome operational and financial barriers to integrating immunotherapy into their practice setting.

Continuing Education Information

Approximate Time to Complete: One hour and 30 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-733-H01-P) 

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.  Designated for 0.2 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Ryan Weight, DO, MD: Consulting Fees - ACCC, Castle Biosciences, Novartis; Fees for Non-CME.CE Services - Merck; Contracted Research - BMS

Monique Giordana, PharmD, BCOP: No conflict of interest to report.

Lisa Kottschade, APRN, MSN, CNP: Consulting Fees - BMS, Array BioPharma

Jodi Nordberg: Fees for Non-CME/CE Services - Genentech

Sara Smith, PharmD, BCOP: Consulting Fees - Takeda

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please following the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for the appropriate course title.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Complete the post-test and survey.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.

Course Description

Exemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

The Immunotherapy for the Treatment of Genitourinary Malignancies module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of Genitourinary Malignancies. The module also includes case studies on immunotherapy for the treatment of Genitourinary Malignancies.

Target Audience

This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
 

Faculty

Lenard J. Appleman, MD, PhD

Associate Professor of Medicine

UPMC Hillman Cancer Center

Learning Objectives

At the conclusion of this activity, the participant should be able to:

1. Describe the rationale for common approaches to cancer immunotherapy for genitourinary malignancies 
2. Identify the appropriate clinical management of common side effects of immunotherapy agents
3. Implement cancer immunotherapy for genitourinary malignancies
4. Become familiar with clincial data on the efficacy of approved therapies
5. Recognize patient selection criteria for approved therapies
6. Select appropriate dosing and sequencing of approved therapies (including timing and combination approaches)

Continuing Education Information

Approximate Time to Complete: 45 minutes

Credit Available: April 25, 2019 - April 25, 2020

Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-19-732-H01-P)

Type of Activity: Knowledge

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Leonard J. Appleman, MD, PhD: Contracted Research - Astellas, BMS, Bayer, Exolius, Merck, Roche

Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 17, 2019 through April 17, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

If you wish to receive acknowledgment for completing this activity, please following the steps below:

1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
2. Under Pending Credit, click Request Credit for the appropriate course title.
3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
4. Complete the post-test and survey.
5. Click Process Credit.
6. Your Certificate will be available to view in the Submitted Credit section. 

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

Media
Internet

Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact PIM: www.pimed.com.